Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

VBLT $3.80 0.5373 +16.48%
NWBO $1.42 0.0799 +5.96%
VRML $1.37 0.0700 +5.38%
CLDX $4.32 0.1700 +4.10%
CASI $1.56 0.0600 +4.00%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CERU $2.77 -0.3300 -10.65%
MACK $6.58 -0.7000 -9.62%
CTIC $0.47 -0.0400 -7.84%
LXRX $13.22 -1.0300 -7.23%
KPTI $8.92 -0.6000 -6.30%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Biden to Cancer Researchers: How Can We Move Faster On This?

(Washington Post/To Your Health) Apr 20, 2016 - Vice President Biden called on the nation's leading cancer researchers to accelerate progress in the fight against the disease by sharply boosting their efforts to collaborate and share data and by giving him advice on how to make the federal government a forceful ally in the anti-cancer effort.
read article (free registration required) 

Downside to Melanoma Immunotherapy: 55% to 67% Nonresponders

(Medscape Medical News) April 20, 2016 - The efficacy of anti-PD-1 agents for advanced melanoma, such as pembrolizumab, has been great news, but not for all patients.
read article (free registration required) 

Express Scripts Countersues Anthem in Contract Dispute

(Wall Street Journal) Apr 19, 2016 - Pharmacy-benefit manager denies claims by Anthem that it refused to renegotiate pricing terms.
read article (paid subscription required) 

Califf: FDA Can't Isolate Itself From Industry, Despite 'Touchy' Issues

(STAT) Apr 19, 2016 - The new Food and Drug Administration chief says the agency has to work with industry groups so it can keep up with the latest developments in medical science — because otherwise, even the agency’s best experts will fall behind.
read article 

How Medicare Penalizes Hospitals for Being Too Careful

(New York Times/Kaiser Health News) Apr 20, 2016 - High rates of infections and other complications are prompting lower payments from Medicare, as well as protests from some elite hospitals.
read article 

Medicare Proposal Would Drop Cuts To Hospitals Based On Two-Midnight Inpatient Rule

(KHN Morning Briefing) Apr 20, 2016 - The wide-ranging proposed rule for hospital payments seeks to mute industry criticism of how federal officials handle reimbursements and classifications for inpatients, as well as overpayments and bundled services.
read article 

Medicare Delays Plans For New Star Ratings On Hospitals After Congressional Pressure

(Kaiser Health News) Apr 20, 2016 - Bowing to pressure from the hospital industry and Congress, the Obama administration on Wednesday delayed releasing its new hospital quality rating measure just a day before its planned launch.
read article 

Dr. Avinash Desai Appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai Inc.

(Morningstar) Apr 20, 2016 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).
read article 

Ohio State Receives Top Rating From National Cancer Institute — ‘Exceptional’ — Re-Designated As Comprehensive Cancer Center

(OSUCCC/The James) Apr 19, 2016 - The Ohio State University Comprehensive Cancer Center (OSUCCC) has again been ranked as “exceptional” and renewed as a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, the highest honor bestowed to a cancer program in the United States.
read press release 

What The Cancer 'Moonshot' Needs To Fix

(Politico/The Agenda) Apr 20, 2016 - It offers a rare chance to address the troubling imbalance in research funding.
read article 

ASCO Urges 2017 NIH, NCI Funding Increase to Regain Ground in Fight Against Cancer

(ASCO in Action) Apr 19, 2016 - ASCO asked for $34.5 billion for NIH and $5.9 billion for NCI.
read article 

ASCO Representative Featured at Public Forum on Medicare Part B Experiment

(ASCO in Action) Apr 19, 2016 - ASCO's Vice President of Clinical Affairs Stephen S. Grubbs, MD, was a featured speaker at a public forum on the Centers for Medicare & Medicaid Services (CMS) proposal outlining a mandatory demonstration project that would reduce the average sales price reimbursement rate for Medicare Part B drugs in certain areas of the country.
read article 

ASCO Lauds MACRA's Focus on Quality and Value; Outlines Path to Implementation for Oncology

(ASCO in Action) Apr 19, 2016 - Statement submitted to Congressional hearing on MACRA implementation.
read article 

Ready or Not. . . More ICD-10-CM Codes Coming October 2016!

(ACCCBuzz) Apr 15, 2016 - The transition to ICD-10-CM diagnosis coding occurred October 1, 2015, but just like ICD-9-CM we will be seeing additions, deletions and revised codes each October until the U.S. moves to ICD-11-CM.
read article 

Technology Supports Care for Patients Demanding More of Their Healthcare

(AJMC) Apr 19, 2016 - With patients increasingly demanding more of anyone involved in their healthcare, technology is playing an important role, explained panelists at a session of Specialty Pharmacy Connect, a pre-meeting program held ahead of the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
read article 

The Future of Specialty Pharmacy: Where Do We Need to Go?

(AJMC) Apr 19, 2016 - The specialty pharmacy industry is unique in many ways, but the price growth for these drugs is no longer sustainable, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
read article 

In the Face of Chronic Pain, Clinicians Seek Best Practices for Management while Evading Opioid Abuse

(NCCN) Apr 15, 2016 - On Saturday, April 2, 2016, during the NCCN 21st Annual Conference, Judith Paice, PhD, RN, FAAN, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discussed best practices in management of chronic pain in people with cancer.
read press release 

For Breast Cancer, When to Screen or Not to Screen? That is the Question Plaguing the Minds of U.S. Women—and Their Clinicians

(NCCN) Apr 18, 2016 - To shed light on the screening conundrum, the National Comprehensive Cancer Network® (NCCN®) brought together experts from the three leading guidelines organizations to discuss the screening controversies during its 21st Annual Conference on April 2, 2016.
read press release 

Compugen’s Cancer Immunotherapy Partnership with Bayer Achieves 1st Preclinical Milestone

(Immuno-Oncology News) Apr 20, 2016 - Compugen announced it has achieved its first preclinical milestone with its immune checkpoint target candidate CGEN-15022, a result of its cancer immunotherapy collaboration with Bayer.
read article 

University of Chicago, AbbVie Sign Cancer Research Deal

(Chicago Tribune) Apr 20, 2016 - Leukemia patients got a ray of hope last week when the U.S. Food and Drug Administration approved a new drug that targets a subset of leukemia patients with a genetic abnormality that makes the cancer harder to treat.
read article 

FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma

(Spectrum) Apr 20, 2016 - Spectrum Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted 7 years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
read corporate press release 

Lion Biotechnologies Manufacturing Capabilities And Research Programs Unaffected By Review Of National Cancer Institute's Manufacturing Facilities

(Lion Biotechnologies) Apr 17, 2016 - Lion's phase 2 study of lead product, LN-144, for the treatment of refractory, metastatic melanoma continues uninterrupted.
read corporate press release 

Kite Pharma Announces Review of National Cancer Institute's Manufacturing Facilities

(Kite Pharma) Apr 16, 2016 - Kite's four ongoing multi-center clinical trials of its lead product candidate, KTE-C19, are continuing; Kite remains on track to file an investigational new drug application (IND) with the Food and Drug Administration (FDA) by the end of this year for a T cell receptor (TCR)-based product candidate targeting a MAGE antigen for the treatment of certain solid tumors.
read corporate press release 

BioSight Completed Treatment of Patients in Astarabine™ Phase I/IIa Clinical Trial

(Yahoo! Finance) Apr 19, 2016 - Results to date indicate superior safety and efficacy in secondary AML and newly-diagnosed AML and ALL patients unfit for conventional chemotherapy.
read article 

Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor

(Virtual-Strategy Magazine) Apr 19, 2016 - Results highlighted in oral presentation at the 2016 American Association For Cancer Research (AACR) annual meeting; Atara Bio and QIMR Berghofer collaborating to develop next generation "off-the-shelf" T cell immunotherapy for NPC and other diseases.
read article